Insider Deal: Tracy Marshbanks Sold 1,912 Shares of ANI Pharmaceuticals, Inc. (ANIP); 12 Bullish Analysts Covering Qurate Retail Group, Inc. (QVCA)

The insider, and Ani Pharmaceuticals Inc’s director, Tracy Marshbanks, sold 1,912 company shares on 16-03-2018, worth total $120,647 (at $63.1 for each one share). She also sold 64,221 shares with a total value $4,047,888 USD in the last 30 days. The dated 16-03-2018 transaction’s document which was filed with the U.S. Security & Exchange Commission is freely available for public review here. Due to the significance of this transaction, it will not go disregarded. Tracy Marshbanks owns 4.15% of the -company’s market cap with a total of 483,801 shares.

Among 14 analysts covering Liberty Interactive (NASDAQ:QVCA), 12 have Buy rating, 1 Sell and 1 Hold. Therefore 86% are positive. Liberty Interactive had 33 analyst reports since August 6, 2015 according to SRatingsIntel. On Thursday, June 9 the stock rating was initiated by Maxim Group with “Buy”. The firm has “Outperform” rating given on Wednesday, August 10 by FBN Securities. Axiom Capital maintained the shares of QVCA in report on Friday, November 13 with “Buy” rating. The rating was maintained by Aegis Capital with “Buy” on Tuesday, February 27. The firm earned “Sell” rating on Thursday, September 28 by Citigroup. Bank of America maintained Qurate Retail Group, Inc. (NASDAQ:QVCA) rating on Friday, March 2. Bank of America has “Buy” rating and $36 target. The rating was initiated by Pacific Crest on Tuesday, December 8 with “Overweight”. Axiom Capital maintained the stock with “Buy” rating in Thursday, August 6 report. As per Friday, August 12, the company rating was maintained by FBR Capital. Aegis Capital maintained Qurate Retail Group, Inc. (NASDAQ:QVCA) on Friday, July 7 with “Buy” rating. See Qurate Retail Group, Inc. (NASDAQ:QVCA) latest ratings:

05/03/2018 Broker: UBS Rating: Buy New Target: $33.0 Maintain
02/03/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $39 New Target: $36 Maintain
02/03/2018 Broker: FBN Securities Old Rating: Outperform New Rating: Sector Perform Downgrade
27/02/2018 Broker: Aegis Capital Rating: Buy New Target: $38.0 Maintain
10/01/2018 Broker: KeyBanc Capital Markets Rating: Buy New Target: $28.0 Maintain
03/01/2018 Broker: FBN Securities Rating: Buy Upgrade
10/11/2017 Broker: UBS Rating: Buy Old Target: $27 New Target: $28 Maintain
09/11/2017 Broker: FBR Capital Rating: Buy New Target: $28.0
23/10/2017 Broker: KeyBanc Capital Markets Rating: Buy New Target: $27.0 Maintain
28/09/2017 Broker: Citigroup Rating: Sell New Target: $22.0 Downgrade

The stock increased 2.76% or $0.75 during the last trading session, reaching $27.93. About 2.34M shares traded. Qurate Retail Group, Inc. (NASDAQ:QVCA) has declined 6.46% since March 17, 2017 and is downtrending. It has underperformed by 23.16% the S&P500.

QVC Group markets and sells various consumer products primarily through live merchandise-focused televised shopping programs, Internet, and mobile applications. The company has market cap of $13.31 billion. The company’s Websites offers home, apparel, beauty, accessories, jewelry, and electronics products. It has a 10.34 P/E ratio. It also operates as an online retailer of women’s, children’s, and men’s apparel, and children’s merchandise; and kitchen accessories and home décor products, as well as retails its products through catalogs, and brick-and-mortar stores.

Analysts await ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) to report earnings on May, 3. They expect $1.10 EPS, up 77.42% or $0.48 from last year’s $0.62 per share. ANIP’s profit will be $12.82M for 14.05 P/E if the $1.10 EPS becomes a reality. After $1.00 actual EPS reported by ANI Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 10.00% EPS growth.

Since March 1, 2018, it had 0 insider purchases, and 5 selling transactions for $9.28 million activity. MARSHBANKS TRACY had sold 64,221 shares worth $4.05M. On Monday, March 5 the insider Marken James G. sold $258,640. 23,986 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shares with value of $1.47M were sold by PRZYBYL ARTHUR. RAYNOR DANIEL sold 27,964 shares worth $1.74 million. Another trade for 28,652 shares valued at $1.77 million was sold by Schrepfer Robert W.

Investors sentiment decreased to 1.09 in Q3 2017. Its down 0.60, from 1.69 in 2017Q2. It is negative, as 16 investors sold ANI Pharmaceuticals, Inc. shares while 26 reduced holdings. 22 funds opened positions while 49 raised stakes. 6.31 million shares or 1.29% less from 6.39 million shares in 2017Q2 were reported. California Public Employees Retirement Systems invested in 0% or 17,700 shares. Nomura invested in 0.03% or 240,528 shares. 8,567 are held by Dupont Capital Mgmt Corp. Pinebridge Invs Limited Partnership reported 0% stake. Mangrove Prtnrs, a New York-based fund reported 376,314 shares. Moreover, Farmers And Merchants Investments has 0% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 131 shares. Fifth Third Savings Bank owns 9,247 shares. Moreover, Jpmorgan Chase Communications has 0% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 104,829 shares. State Street reported 271,593 shares. Ameriprise Fincl stated it has 0% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Lsv Asset Management has invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Blackrock has invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Tci Wealth Advisors has invested 0% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Wells Fargo And Mn, a California-based fund reported 11,215 shares. Texas Permanent School Fund invested in 0% or 6,542 shares.

The stock increased 3.50% or $2.09 during the last trading session, reaching $61.84. About 230,826 shares traded or 61.59% up from the average. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has declined 0.02% since March 17, 2017 and is downtrending. It has underperformed by 16.72% the S&P500.